We run a range of clinical trials for many diseases — see below for all current trials and ongoing programs. If appropriate, please consider participating: you'll be helping us create a healthier future for all.
The benefits of clinical trials:
- enable deep insights and understanding of disease
- identify new treatments and therapies
- help decide government funding for new drugs.
All our trials adhere to strict protocols around safety, ethics and privacy.
An Australian-led research project at the Garvan Institute, funded by the National Health and Medical Research Council, is recruiting volunteers for a 3-year study examining the effects of metformin on cognition, brain anatomy and early signs of dementia.
We’re looking for people who meet the following eligibility criteria:
- Live in the greater Sydney region;
- Are over 60 years of age;
- Are slightly overweight but do not have diabetes;
- Do not have dementia;
- Have concerns about changes in memory or thinking;
- Are not currently taking metformin.
Metformin is a safe medication used to treat diabetes, but also other metabolic/hormonal conditions.
Our aims are to slow loss of memory and other aspects of cognition with ageing, and examine whether metformin affects other aspects of metabolism, inflammation and the ageing process.
Our team is made up of leading Australian and US dementia researchers, including:
|Professor Katherine Samaras||Professor Richard Day|
|Professor Perminder Sachdev||Professor Peter MacDonald|
|Professor Henry Brodaty||Dr Nicole Kochan|
|Professor Maria Fiatarone-Singh||A/Professor Wei Wen|
|Professor Jose Luchsinger – Columbia University, New York||In concert with representatives from Alzheimer’s Australia.|
For more information, contact by telephone or email:
Phone number: (02) 9295-8585
This study is funded by the National Health and Medical Research Council (#1171665)
This study has been approved by the St Vincent’s Hospital Human Research Ethics Committee
(HREC 2020 / 01652)
The molecular screening and therapeutic trials (MoST) personalises experimental treatment based on an individual’s unique personal and cancer genetic profile, for patients with rare cancers.
- The eligibility to participate in these trials may vary on a case by case basis.
The Personalised Medicine in Prediabetes – Towards Preventing Diabetes in Individuals at Risk (PREDICT) Study aims to test the efficacy of metformin administered with a personalised diet on blood sugar control in adults with prediabetes or early-stage type 2 diabetes.
- Men and women aged 20-70 years who have pre-diabetes (i.e. you've been told you're at risk of developing type 2 diabetes, or you have had increased blood sugar in previous blood tests)
- Been recently diagnosed with type 2 diabetes (and not yet treated with a sugar-lowering medication).
Phone: 9295 8215
The Australian Parkinson's Mission will conduct a clinical trial program using repurposed drugs, integrated with transformative research, to identify effective treatments for people with Parkinson’s.
- The clinical trials are open to all people with Parkinson's disease — those who have been newly diagnosed, and those have been living with the disease.
Phone: 1300 770 577
Currently, there are a number of clinical trials running at the Kinghorn Cancer Centre for patients with early, advanced breast cancer and for patients undergoing breast cancer surgery.
- The eligibility to participate in these trials may vary on a case by case basis
Aura Serrano, Breast Cancer Clinical Research Nurse
Phone: 02 9355 5723
Absorption of Ursolic acid in males
This trial aims to investigate the absorption profile of the nutritional supplement Ursolic acid. Studies in animals suggest it has the potential to help build muscle and prevent it from wasting away. Ursolic acid can be found in fruit and vegetables, however not much is absorbed. This study aims to determine the bio-availability, safety, and tolerability of ursolic acid.
- Healthy male aged between 18-35 years’ old
- A BMI of > 18 and <27.99 kg/m2
Dr Gareth Fletcher, Research Officer
Insulin Resistance in Type 1 Diabetes managed with METformin (INTIMET study)
The INTIMET study aims to investigate the effects of metformin on hepatic and peripheral insulin resistance in adults with type 1 diabetes.
- Type 1 diabetes:
Diagnosis more than 10 years ago
HbA1c < 9.5%
- People without diabetes:
Type 1 diabetes:
4 total visits: ie 2 visits before and after 6 months treatment with metformin or placebo
People without diabetes:
2 visits (no treatment with medication)
Dr Jennifer Snaith